Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PL-3994 in Controlled Hypertension
NCT00686803Phase 2Completed
- Sponsor
- Palatin Technologies, Inc.
- Start
- Apr 2008
- Primary completion
- Jul 2008
- Modality
- Peptides, Small Molecules
01
Overview
Phase 2, randomised, double-blind trial of PL-3994 in hypertension (HTN) (6 arms), sponsored by Palatin Technologies, Inc. Primary endpoints: Pharmacokinetics at 24 hours and Cyclic Guanosine Monophosphate Levels at 24 hours. Started Apr 2008; status: completed.
02
Drugs
PL-3994
03
Conditions
hypertension (HTN)
Beyond the preview
Go deeper on NCT00686803.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00686803.